CLEARWATER, Fla., March 27, 2006 (PRIMEZONE) -- Maui General Stores, Inc. (OTCBB:MAUG) dba Trinity BioGenics Corp., a research and development company focused on making Adult Stem Cell procedures commercially available in conjunction with Immune Therapy, is pleased to announce it has retained the services of AGORACOM Investor Relations Corp. ("AGORACOM") (http://www.agoracom.com) to provide investor relations services.
The objective of this agreement is two-fold. First, to create effective communication between Trinity BioGenics, its shareholders and the investment community through AGORACOM's Internet based investor relations system. Effective immediately, a customized and monitored Trinity BioGenics IR HUB (http://www.agoracom.com/IR/TrinityBioGenics) will allow both Trinity BioGenics and AGORACOM to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications. The IR HUB will also provide one-click access to the Trinity BioGenics broker fact sheet, company profile, most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the Company that is free of spam, bashing, hyping and profanity.
Second, AGORACOM will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
Trinity BioGenics Chairman and CEO, Dr. Lawrence Stowe, stated, "Given the Company's recent developments, we believe the time has now come to significantly increase our communications with shareholders and the investment community. The solution provided by AGORACOM fulfils our need to manage and execute an IR strategy in a cost efficient manner, while providing our management team with the ability to focus on executing the business plan. Our shareholders and Company will benefit greatly from near real-time communications, regularly planned updates and increased exposure."
For all future Trinity BioGenics investor relations needs, investors are asked to visit the Trinity BioGenics IR Hub at http://www.agoracom.com/IR/TrinityBioGenics where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors are able to e-mail all questions and correspondence to MAUG@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.
This agreement has been negotiated entirely at arm's length. AGORACOM is located in Toronto, Ontario.
More information about Trinity BioGenics Corp. may be found at: http://trinitybiogenics.com
About AGORACOM Investor Relations Corp.
http://www.agoracom.com http://www.AgoraIR.com
AGORACOM Investor Relations Corp. (AGORACOM) is North America's leading outsourced investor relations firm for small-cap companies. AGORACOM's exclusive IR HUB delivers two-way investor relations and communications that provides 100% transparency, accessibility, equality and near real-time communications for all shareholders and the investment community. The digital delivery of investor relations also provides public companies with savings over traditional services ranging from 50-60%.
AGORACOM has specialized in small-cap investor relations since 1997 and is the exclusive provider of all content to the AOL Small Cap Channel.
About Trinity BioGenics Corp.
Trinity BioGenics Corp works exclusively within the Adult Stem Cell and Biological Medicine areas. The Company's proprietary protocols are advanced, and use specific processes to obtain desired results. The FDA classifies the Company's process as a unique blood product; therefore, it will be specific and unique to Trinity BioGenics Corp. Additionally, the Company's unique combination of Immune Therapy and Adult Stem Cell treatments are like no other treatment experienced. The Company's Adult Stem Cell protocol is under preparation for Human Clinical Studies.
The Maui General Store logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=1128